Staff Members - Benha University
The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin
Biology (Basel). • 2019
Publication Information
Authors
Lamiaa M. Shawky 1, Ahmed A. Morsi 2,*, Eman El Bana 3 and Safaa Masoud Hanafy 4
Keywords
sitagliptin; immunohistochemistry; insulin; caspase-3; iNOS; HFD/STZ diabetes;
pancreas; rat
Journal
Biology (Basel).
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Abstract: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a beneficial class of antidiabetic
drugs. However, a major debate about the risk of developing pancreatitis is still existing. The aim
of the work was to study the histological and immunohistochemical e ects of sitagliptin on both
endocrine and exocrine pancreases in a rat model of type 2 diabetes mellitus and to correlate
these e ects with the biochemical findings. Moreover, a possible synergistic e ect of sitagliptin,
in combination with metformin, was also evaluated. Fifty adult male rats were used and assigned
into five equal groups. Group 1 served as control. Group 2 comprised of untreated diabetic rats.
Group 3 diabetic rats received sitagliptin. Group 4 diabetic rats received metformin. Group 5 diabetic
rats received both combined. Treatments were given for 4 weeks after the induction of diabetes.
Blood samples were collected for biochemical assay before the sacrification of rats. Pancreases were
removed, weighed, and were processed for histological and immunohistochemical examination. In the
untreated diabetic group, the islets appeared shrunken with disturbed architecture and abnormal
immunohistochemical reactions for insulin, caspase-3, and inducible nitric oxide synthase (iNOS).
The biochemical findings were also disturbed. Morphometrically, there was a significant decrease in
the islet size and islet number. Treatment with sitagliptin, metformin, and their combination showed
an improvement, with the best response in the combined approach. No evidence of pancreatic injury
was identified in the sitagliptin-treated groups. In conclusion, sitagliptin had a cytoprotective e ect
on beta-cell damage. Furthermore, the data didn’t indicate any detrimental e ects of sitagliptin on
the exocrine pancreas.
drugs. However, a major debate about the risk of developing pancreatitis is still existing. The aim
of the work was to study the histological and immunohistochemical e ects of sitagliptin on both
endocrine and exocrine pancreases in a rat model of type 2 diabetes mellitus and to correlate
these e ects with the biochemical findings. Moreover, a possible synergistic e ect of sitagliptin,
in combination with metformin, was also evaluated. Fifty adult male rats were used and assigned
into five equal groups. Group 1 served as control. Group 2 comprised of untreated diabetic rats.
Group 3 diabetic rats received sitagliptin. Group 4 diabetic rats received metformin. Group 5 diabetic
rats received both combined. Treatments were given for 4 weeks after the induction of diabetes.
Blood samples were collected for biochemical assay before the sacrification of rats. Pancreases were
removed, weighed, and were processed for histological and immunohistochemical examination. In the
untreated diabetic group, the islets appeared shrunken with disturbed architecture and abnormal
immunohistochemical reactions for insulin, caspase-3, and inducible nitric oxide synthase (iNOS).
The biochemical findings were also disturbed. Morphometrically, there was a significant decrease in
the islet size and islet number. Treatment with sitagliptin, metformin, and their combination showed
an improvement, with the best response in the combined approach. No evidence of pancreatic injury
was identified in the sitagliptin-treated groups. In conclusion, sitagliptin had a cytoprotective e ect
on beta-cell damage. Furthermore, the data didn’t indicate any detrimental e ects of sitagliptin on
the exocrine pancreas.